Literature DB >> 33205306

Alteration of FBXW7 is Associated with Worse Survival in Patients Undergoing Resection of Colorectal Liver Metastases.

Yoshikuni Kawaguchi1, Timothy E Newhook1, Hop S Tran Cao1, Ching-Wei D Tzeng1, Yun Shin Chun1, Thomas A Aloia1, Arvind Dasari2, Scott Kopetz2, Jean-Nicolas Vauthey3.   

Abstract

BACKGROUND: For patients undergoing resection of colorectal liver metastases (CLMs), the prognostic role of somatic gene alterations is increasingly recognized. F-box/WD repeat-containing protein 7 (FBXW7) is a tumor suppressor gene found in approximately 10% of patients with colorectal cancer. The aim of this study is to assess the association of FBXW7 with overall survival after CLM resection.
METHODS: Patients who underwent initial CLM resection during 2001-2016 and had genetic sequencing data were studied. Risk factors for overall survival (OS) were evaluated with Cox proportional hazards models using backward elimination.
RESULTS: Of 2045 patients who underwent CLM resection during the study period, 476 were included. The majority (90.5%) underwent prehepatectomy chemotherapy. A total of 27 patients (5.7%) had FBXW7 alteration, along with 240 (50.4%) RAS, 337 (70.8%) TP53, 51 (10.7%) SMAD4, and 27 (5.7%) BRAF. Cox proportional hazards model analyses including 5 somatic gene alteration status and 12 clinicopathologic factors revealed FBXW7(hazard ratio [HR] 1.99, P = 0.015), BRAF (HR 2.47, P = 0.023), RAS (HR 2.42, P < 0.001), TP53 (HR 2.00, P < 0.001), and SMAD4 alterations (HR 1.90, P = 0.004) as significantly associated with OS, together with three clinicopathologic factors, prehepatectomy chemotherapy > 6 cycles (HR 1.51, P = 0.021), number of CLM (HR 1.05, P = 0.007), and largest liver metastasis diameter (HR 1.07, P = 0.023). The covariate-adjusted 5-year OS was significantly lower in patients with FBXW7 alteration than in patients with FBXW7 wild-type (40.4% vs.59.4%, P = 0.015).
CONCLUSIONS: FBXW7 alterations are associated with worse survival after CLM resection. The information on multiple somatic gene alterations is imperative for risk stratification and patient selection for CLM resection.

Entities:  

Keywords:  Genetic sequencing; Liver resection; Metastatic colorectal cancer; Mutation; Somatic gene alteration

Mesh:

Substances:

Year:  2020        PMID: 33205306     DOI: 10.1007/s11605-020-04866-2

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  22 in total

1.  Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.

Authors:  Georgios Antonios Margonis; Stefan Buettner; Nikolaos Andreatos; Yuhree Kim; Doris Wagner; Kazunari Sasaki; Andrea Beer; Christoph Schwarz; Inger Marie Løes; Maria Smolle; Carsten Kamphues; Jin He; Timothy M Pawlik; Klaus Kaczirek; George Poultsides; Per Eystein Lønning; John L Cameron; Richard A Burkhart; Armin Gerger; Federico N Aucejo; Martin E Kreis; Christopher L Wolfgang; Matthew J Weiss
Journal:  JAMA Surg       Date:  2018-07-18       Impact factor: 14.766

2.  RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.

Authors:  Jean-Nicolas Vauthey; Giuseppe Zimmitti; Scott E Kopetz; Junichi Shindoh; Su S Chen; Andreas Andreou; Steven A Curley; Thomas A Aloia; Dipen M Maru
Journal:  Ann Surg       Date:  2013-10       Impact factor: 12.969

Review 3.  Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

Authors:  K W Brudvik; S E Kopetz; L Li; C Conrad; T A Aloia; J-N Vauthey
Journal:  Br J Surg       Date:  2015-07-21       Impact factor: 6.939

4.  Conditional Recurrence-Free Survival after Resection of Colorectal Liver Metastases: Persistent Deleterious Association with RAS and TP53 Co-Mutation.

Authors:  Yoshikuni Kawaguchi; Heather A Lillemoe; Elena Panettieri; Yun Shin Chun; Ching-Wei D Tzeng; Thomas A Aloia; Scott Kopetz; Jean-Nicolas Vauthey
Journal:  J Am Coll Surg       Date:  2019-05-02       Impact factor: 6.113

5.  Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients.

Authors:  Myrddin Rees; Paris P Tekkis; Fenella K S Welsh; Thomas O'Rourke; Timothy G John
Journal:  Ann Surg       Date:  2008-01       Impact factor: 12.969

6.  The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.

Authors:  Katsumi Amikura; Kiwamu Akagi; Toshiro Ogura; Amane Takahashi; Hirohiko Sakamoto
Journal:  J Surg Oncol       Date:  2017-11-30       Impact factor: 3.454

7.  Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases.

Authors:  Yun Shin Chun; Guillaume Passot; Suguru Yamashita; Maliha Nusrat; Panagiotis Katsonis; Jonathan M Loree; Claudius Conrad; Ching-Wei D Tzeng; Lianchun Xiao; Thomas A Aloia; Cathy Eng; Scott E Kopetz; Olivier Lichtarge; Jean-Nicolas Vauthey
Journal:  Ann Surg       Date:  2019-05       Impact factor: 12.969

8.  KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases.

Authors:  Garrett M Nash; Mark Gimbel; Jinru Shia; Daniel R Nathanson; MacKevin I Ndubuisi; Zhao-Shi Zeng; Nancy Kemeny; Philip B Paty
Journal:  Ann Surg Oncol       Date:  2009-09-01       Impact factor: 5.344

9.  Extended Molecular Profiling Improves Stratification and Prediction of Survival After Resection of Colorectal Liver Metastases.

Authors:  Hauke Lang; Janine Baumgart; Stefan Heinrich; Verena Tripke; Monia Passalaqua; Annett Maderer; Peter R Galle; Wilfried Roth; Michael Kloth; Markus Moehler
Journal:  Ann Surg       Date:  2019-11       Impact factor: 12.969

10.  Long-term postoperative survival prediction in patients with colorectal liver metastasis.

Authors:  Kun Wang; Wei Liu; Xiao-Luan Yan; Juan Li; Bao-Cai Xing
Journal:  Oncotarget       Date:  2017-08-18
View more
  2 in total

Review 1.  Colorectal liver metastases: state-of-the-art management and surgical approaches.

Authors:  Timothy E Newhook; Jean-Nicolas Vauthey
Journal:  Langenbecks Arch Surg       Date:  2022-04-09       Impact factor: 2.895

2.  Contour prognostic model for predicting survival after resection of colorectal liver metastases: development and multicentre validation study using largest diameter and number of metastases with RAS mutation status.

Authors:  Y Kawaguchi; S Kopetz; H S Tran Cao; E Panettieri; M De Bellis; Y Nishioka; H Hwang; X Wang; C-W D Tzeng; Y S Chun; T A Aloia; K Hasegawa; A Guglielmi; F Giuliante; J-N Vauthey
Journal:  Br J Surg       Date:  2021-08-19       Impact factor: 6.939

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.